Home  »  Business   »  Is This The Best Time To Buy Iovance Biotherapeuti...

Is This The Best Time To Buy Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Stock?

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) traded at $7.00 at close of the session on Monday, 01/23/23, made an upward move of 11.64% on its previous day’s price.

Looking at the stock we see that its previous close was $6.27 and the beta (5Y monthly) reads 0.12 with the day’s price range being $6.50 – $7.115. In terms of its 52-week price range, IOVA has a high of $18.73 and a low of $5.42. The company’s stock has gained about 14.75% over that past 30 days.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Iovance Biotherapeutics Inc. has a market cap of $1.09 billion and is expected to release its quarterly earnings report on Feb 22, 2023 – Feb 27, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.64, with the EPS growth for the year raised at -$2.5 for 2022 and -$2.41 for next year. These figures represent -12.10% and 3.60% growth in EPS for the two years respectively.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the IOVA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 15 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the Iovance Biotherapeutics Inc. (IOVA) stock as a Hold, while 9 rate it as a Buy. 2 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 13.07% off its SMA20 and 5.19% from its 50-day simple moving average. The RSI (14) is pointing at 59.56 while the volatility over the past week is 6.02% and jumps to 6.41% over the past one month. The beta value is 0.12, while the average true range (ATR) is currently pointing at 0.43. The average price target for the stock over the next 12 months is $23.33, with the estimates having a low of $6.00 and a high of $40.00. These price ends are 14.29% and -471.43% off the current price level respectively, although investors could be excited at the prospect of a -250.0% if the IOVA share price touches on the median price of $24.50.

Let’s briefly compare Iovance Biotherapeutics Inc. (IOVA) stock to its peers. We find that current price change of 11.64% and -50.14% over the past 12 months for IOVA competes that of Pfizer Inc. (PFE), which has seen its stock price fall -0.29% in the last trading session and was -16.78% over the last one year. Another of its peers Merck & Co. Inc. (MRK) has dropped -0.05% previous session, and was 36.07% up over the past year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.19% and 0.76%, respectively, at close of the trading.

Coming back to Iovance Biotherapeutics Inc. (NASDAQ:IOVA), we note that the average 3-month trading volume was 4.24 million, while that of the preceding 10-day period stands at 3.98 million. Current shares outstanding are 157.82 million.

The insiders hold 0.10% of the company’s shares. The data shows that short shares as of Dec 29, 2022, stood at 21.7 million at a short ratio of 3.61. This represents a 13.75% short interest in shares outstanding on Dec 29, 2022. Shares short rose in December from the previous month at 18.72 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 9.55% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *